Status:

COMPLETED

A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis

Lead Sponsor:

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Conditions:

Erectile Disfunction

Hemodialysis

Eligibility:

MALE

19+ years

Phase:

PHASE4

Brief Summary

The study was done to evaluate the efficacy, safety, and tolerability of orally administered sildenafil taken as needed about one hour before sexual activity after a 10-week period in male outpatients...

Eligibility Criteria

Inclusion

  • Included patients had been in a stable relationship with a female partner for at least 6 months
  • A diagnosis of renal failure, with creatinine clearance ≤10 ml/min; been under hemodialysis for at least 6 months prior to the screening period, and a clinical diagnosis of erectile dysfunction (ED) as confirmed by International Index of Erectile Function (IIEF-5) score of \<21 and defined as an "incapacity to obtain and/or maintain an erection sufficient for a satisfactory sexual performance".

Exclusion

  • Patients in regular use of nitrates or nitric oxide donor drugs, or have received a prescription to use these substances in any formulation
  • Patients with genital anatomic malformation that may significantly impair erection (e.g., serious penile fibrosis)
  • Patients with other sexual disorders (e.g., hypoactive sexual desire) considered as a primary diagnosis, with a coexisting ED diagnosis, including patients receiving anti-androgenic therapy whose libido has not been preserved; patients receiving hormonal replacement therapy for at least 6 months, or whose dose has not been stabilized within the last 6 months before the study screening period
  • Patients with diabetes mellitus presenting poor control of their diabetes and/or proliferate diabetes retinopathy.

Key Trial Info

Start Date :

October 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2005

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00654017

Start Date

October 1 2002

End Date

April 1 2005

Last Update

February 1 2021

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Pfizer Investigational Site

Fortaleza, Ceará, Brazil, 60430-370

2

Pfizer Investigational Site

Belo Horizonte, Minas Gerais, Brazil, 30150-260

3

Pfizer Investigational Site

Belo Horizonte, Minas Gerais, Brazil

4

Pfizer Investigational Site

Londrina, Paraná, Brazil, 86010-010